IN8bio (INAB) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
IN8bio (INAB) has outperformed Passage Bio (PASG) over the past year, losing 42.5% versus a loss of 57.5%. Over five years, PASG leads with a -98.1% price change compared with -99.3% for INAB. IN8bio is the larger company by market cap ($13.2 million vs $11.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | PASG |
|---|---|---|
| Share price | $1.34 | $3.69 |
| Market cap | $13.21M | $11.87M |
| 1-day change | -2.90% | -1.07% |
| YTD return | -42.74% | -68.73% |
| 1-year return | -42.49% | -57.51% |
| 5-year return | -99.26% | -98.11% |
| EPS (TTM) | $-1.62 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $20.00 |
| 52-week low | $0.88 | $3.29 |
| Distance from 52-week high | -50.92% | -81.55% |
| Analyst consensus | none | buy |
| Avg. price target upside | +422.39% | +320.05% |
| Average volume | 57.49K | 25.89K |
| Shares outstanding | 9.86M | 3.22M |
| Employees | 18 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed PASG by 15.0 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
INAB vs PASG FAQ
Which is bigger, IN8bio or Passage Bio?
IN8bio (INAB) is larger, with a market capitalization of $13.21M compared with $11.87M for Passage Bio (PASG).
Which stock has performed better over the past year, INAB or PASG?
INAB returned -42.49% over the past 12 months, compared with -57.51% for PASG (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.